These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24372539)

  • 1. De novo design of drug-like molecules by a fragment-based molecular evolutionary approach.
    Kawai K; Nagata N; Takahashi Y
    J Chem Inf Model; 2014 Jan; 54(1):49-56. PubMed ID: 24372539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In Silico Drug Design Using an Evolutionary Algorithm and Compound Database].
    Kawai K; Takahashi Y
    Yakugaku Zasshi; 2016; 136(1):107-12. PubMed ID: 26725677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical fragment spaces for de novo design.
    Mauser H; Stahl M
    J Chem Inf Model; 2007; 47(2):318-24. PubMed ID: 17300171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space.
    Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A
    J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flux (2): comparison of molecular mutation and crossover operators for ligand-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2007; 47(2):656-67. PubMed ID: 17315990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SABRE: ligand/structure-based virtual screening approach using consensus molecular-shape pattern recognition.
    Wei NN; Hamza A
    J Chem Inf Model; 2014 Jan; 54(1):338-46. PubMed ID: 24328054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing discovery efficiency with a computationally driven fragment approach.
    Moore WR
    Curr Opin Drug Discov Devel; 2005 May; 8(3):355-64. PubMed ID: 15892251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of new bioactive molecules using a Bayesian belief network.
    Abdo A; Leclère V; Jacques P; Salim N; Pupin M
    J Chem Inf Model; 2014 Jan; 54(1):30-6. PubMed ID: 24392938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational approach to de novo discovery of fragment binding for novel protein states.
    Konteatis ZD; Klon AE; Zou J; Meshkat S
    Methods Enzymol; 2011; 493():357-80. PubMed ID: 21371598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo design - hop(p)ing against hope.
    Schneider G
    Drug Discov Today Technol; 2013 Dec; 10(4):e453-60. PubMed ID: 24451634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization.
    Hartenfeller M; Proschak E; Schüller A; Schneider G
    Chem Biol Drug Des; 2008 Jul; 72(1):16-26. PubMed ID: 18564216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment library design: using cheminformatics and expert chemists to fill gaps in existing fragment libraries.
    Kutchukian PS; So SS; Fischer C; Waller CL
    Methods Mol Biol; 2015; 1289():43-53. PubMed ID: 25709032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flux (1): a virtual synthesis scheme for fragment-based de novo design.
    Fechner U; Schneider G
    J Chem Inf Model; 2006; 46(2):699-707. PubMed ID: 16563000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo drug design using multiobjective evolutionary graphs.
    Nicolaou CA; Apostolakis J; Pattichis CS
    J Chem Inf Model; 2009 Feb; 49(2):295-307. PubMed ID: 19434831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards structure-based protein drug design.
    Zhang C; Lai L
    Biochem Soc Trans; 2011 Oct; 39(5):1382-6, suppl 1 p following 1386. PubMed ID: 21936819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking.
    Kolb P; Caflisch A
    J Med Chem; 2006 Dec; 49(25):7384-92. PubMed ID: 17149868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico fragment-based drug design using a PASS approach.
    Filz OA; Lagunin AA; Filimonov DA; Poroikov VV
    SAR QSAR Environ Res; 2012; 23(3-4):279-96. PubMed ID: 22372682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.